Threonine

Threonine

SCHEMBL668806

C[C@@H](O)[C@H](N)C(=O)O.C[C@@H](OC(=O)[C@@H](N)Cc1c[nH]cn1)[C@H](N)C(=O)O

nearest known ligand 0.34

Full drug profile on Sugi Atlas →

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CASR P41180 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14809829 0.96 CASR (0.36) CASR
Alanine SCHEMBL6724963 0.94 CASR (0.34) CASR
Histidine SCHEMBL7686781 0.87 SLC7A5 (0.46)
Histidine SCHEMBL6426902 0.86 SLC7A5 (0.40)
Histidine SCHEMBL6426901 0.86 SLC7A5 (0.40)
Histidine SCHEMBL668807 0.86 SLC7A5 (0.40)
Histidine SCHEMBL28805947 0.86 SLC7A5 (0.40)
Lysine SCHEMBL18297991 0.86 GSR (0.41) CASR
Histidine SCHEMBL6947394 0.85 CYP3A4 (0.32) CASR
Histidine SCHEMBL6724968 0.84 SLC7A5 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108586615-B Modified IgG4 bispecific antibodies of sequence symmetry UCB生物制药有限责任公司 2022-03-08 CN claimed
CN-105859876-B Improved IgG4 class antibodies UCB医药有限公司 2021-04-02 CN claimed
EP-3670531-A1 ASYMMETRIC, MODIFIED IGG4 BISPECIFIC ANTIBODIES UCB Biopharma SRL (BE) 2020-06-24 EP claimed
US-20200157204-A1 Antibodies of the Class IGG4 UCB Biopharma SRL (BE) 2020-05-21 US claimed
EP-3156416-B1 SEQUENCE SYMMETRIC MODIFIED IGG4 BISPECIFIC ANTIBODIES UCB BIOPHARMA SPRL (BE) 2019-11-20 EP claimed
CN-108586615-A The IgG4 bispecific antibodies of the modification of sequence symmetry UCB医药有限公司 2018-09-28 CN claimed
CN-104321341-B Modified IgG4 bispecific antibodies of sequence symmetry UCB医药有限公司 2018-05-22 CN claimed
US-9902768-B2 Sequence asymmetric modified IgG4 bispecific antibodies UCB BIOPHARMA SPRL (BE) 2018-02-27 US claimed
EP-2606063-B1 IMPROVED ANTIBODIES OF THE CLASS IGG4 UCB BIOPHARMA SPRL (BE) 2017-05-17 EP claimed
EP-3156416-A1 SEQUENCE SYMMETRIC MODIFIED IGG4 BISPECIFIC ANTIBODIES UCB Biopharma SPRL (BE) 2017-04-19 EP claimed
CN-105859876-A Improved antibodies of the class IgG4 UCB医药有限公司 2016-08-17 CN claimed
EP-2817332-B1 SEQUENCE SYMMETRIC MODIFIED IGG4 BISPECIFIC ANTIBODIES UCB BIOPHARMA SPRL (BE) 2016-07-20 EP claimed
CN-103097410-B Improved IgG4 class antibodies UCB PHARMA S.A. (BE) 2016-06-01 CN claimed
EP-2817333-A1 SEQUENCE SYMMETRIC MODIFIED IGG4 BISPECIFIC ANTIBODIES UCB Pharma, S.A. (BE) 2014-12-31 EP claimed
EP-2817332-A1 SEQUENCE SYMMETRIC MODIFIED IGG4 BISPECIFIC ANTIBODIES UCB Pharma S.A. (BE) 2014-12-31 EP claimed
US-20130323236-A1 Antibodies of the Class IGG4 UCB PHARMA S.A. (BE) 2013-12-05 US claimed
WO-2013124451-A1 SEQUENCE SYMMETRIC MODIFIED IGG4 BISPECIFIC ANTIBODIES UCB PHARMA S.A. (BE) 2013-08-29 WO claimed
WO-2013124450-A1 SEQUENCE SYMMETRIC MODIFIED IGG4 BISPECIFIC ANTIBODIES UCB PHARMA S.A. (BE) 2013-08-29 WO claimed
CN-108586615-B Modified IgG4 bispecific antibodies of sequence symmetry UCB生物制药有限责任公司 2022-03-08 CN disclosed
WO-2012022982-A2 IMPROVED ANTIBODIES OF THE CLASS IGG4 UCB PHARMA S.A. (BE) 2012-02-23 WO disclosed